{"success":true,"data":{"pressRelease":{"id":"6462","rtpr_id":"nGNX4zHhWz","ticker":"COLL","exchange":"NASDAQ","all_tickers":["COLL"],"title":"Collegium to Report First Quarter 2026 Financial Results on May 7, 2026","author":"Globe Newswire","published_at":"2026-04-23T12:00:01.310Z","article_body":"STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical,\nInc.\n(https://www.globenewswire.com/Tracker?data=KfCZr-RgrwXz3mxbDe7aDqdbs6dpPoRZ3EygQCLCpsVHYqNKSxXP9AF11oKcOowUDZm3HWuhHPmK0wHffwRqNGkKouPnGuPkhNsI5GFWayVwXlTFVZdvC6Y6MNC719It) (Nasdaq:\nCOLL) today announced that it will report first quarter 2026 financial results\nbefore the market opens on Thursday, May 7, 2026. Following the release of\nthe financials, the Company will host a live conference call and webcast\nat 8:00 a.m. ET.\n\nConference Call Information \nTo access the conference call, please dial (877) 407-8037 (U.S.) or (201)\n689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2026\nEarnings Call.” An audio webcast will be accessible from the Investors\nsection of the Company’s website: www.collegiumpharma.com. The webcast will\nbe available for replay on the Company’s website approximately two hours\nafter the event.\n\nAbout Collegium Pharmaceutical, Inc.\nCollegium is building a leading, diversified biopharmaceutical company\ncommitted to improving the lives of people living with serious medical\nconditions. The Company has a leading portfolio of responsible pain management\nmedications and a rapidly growing neuropsychiatry business driven by JORNAY\nPM®, a differentiated treatment for ADHD. Collegium’s strategy includes\ngrowing its commercial portfolio, with JORNAY PM as the lead growth driver,\nand deploying capital in a disciplined manner. Collegium’s headquarters are\nlocated in Stoughton, Massachusetts. For more information, please visit the\nCompany’s website at www.collegiumpharma.com.\n\nInvestor Contacts:\nIan Karp\nHead of Investor Relations\nir@collegiumpharma.com\n\nDanielle Jesse\nDirector, Investor Relations\nir@collegiumpharma.com\n\nMedia Contact:\nJessica Cotrone\nSenior Vice President, Communications & Corporate Affairs\ncommunications@collegiumpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c9077b27-1a69-42a5-9f77-e39124f4d2a2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4zHhWz","title":"Collegium to Report First Quarter 2026 Financial Results on May 7, 2026","author":"Globe Newswire","ticker":"COLL","created":"2026-04-23T12:00:01.310Z","tickers":["COLL"],"exchange":"NASDAQ","article_body":"STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical,\nInc.\n(https://www.globenewswire.com/Tracker?data=KfCZr-RgrwXz3mxbDe7aDqdbs6dpPoRZ3EygQCLCpsVHYqNKSxXP9AF11oKcOowUDZm3HWuhHPmK0wHffwRqNGkKouPnGuPkhNsI5GFWayVwXlTFVZdvC6Y6MNC719It) (Nasdaq:\nCOLL) today announced that it will report first quarter 2026 financial results\nbefore the market opens on Thursday, May 7, 2026. Following the release of\nthe financials, the Company will host a live conference call and webcast\nat 8:00 a.m. ET.\n\nConference Call Information \nTo access the conference call, please dial (877) 407-8037 (U.S.) or (201)\n689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2026\nEarnings Call.” An audio webcast will be accessible from the Investors\nsection of the Company’s website: www.collegiumpharma.com. The webcast will\nbe available for replay on the Company’s website approximately two hours\nafter the event.\n\nAbout Collegium Pharmaceutical, Inc.\nCollegium is building a leading, diversified biopharmaceutical company\ncommitted to improving the lives of people living with serious medical\nconditions. The Company has a leading portfolio of responsible pain management\nmedications and a rapidly growing neuropsychiatry business driven by JORNAY\nPM®, a differentiated treatment for ADHD. Collegium’s strategy includes\ngrowing its commercial portfolio, with JORNAY PM as the lead growth driver,\nand deploying capital in a disciplined manner. Collegium’s headquarters are\nlocated in Stoughton, Massachusetts. For more information, please visit the\nCompany’s website at www.collegiumpharma.com.\n\nInvestor Contacts:\nIan Karp\nHead of Investor Relations\nir@collegiumpharma.com\n\nDanielle Jesse\nDirector, Investor Relations\nir@collegiumpharma.com\n\nMedia Contact:\nJessica Cotrone\nSenior Vice President, Communications & Corporate Affairs\ncommunications@collegiumpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c9077b27-1a69-42a5-9f77-e39124f4d2a2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-23T12:00:01.412622483Z","server_sent_at_ms":1776945601412},"received_at":"2026-04-23T12:00:01.463Z","source_url":null},"analysis":{"id":"4721","press_release_id":"6462","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Collegium Pharmaceutical announced it will report its first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.\n\nThe company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.\n\nCollegium focuses on responsible pain management medications and neuropsychiatry, with JORNAY PM as its lead growth driver.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":""},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Ian Karp","role":"Head of Investor Relations"},{"name":"Danielle Jesse","role":"Director, Investor Relations"},{"name":"Jessica Cotrone","role":"Senior Vice President, Communications & Corporate Affairs"}],"products":["JORNAY PM"],"companies":[{"name":"Collegium Pharmaceutical, Inc.","ticker":"COLL"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a standard announcement of an upcoming earnings release date and conference call details. It contains no financial results, guidance changes, or material business updates, thus having minimal immediate impact on the stock."},"tickerRelevance":{"others":[],"primary":"COLL"},"eventTypeSecondary":[]},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Collegium Pharmaceutical announced it will report its first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.\n\nThe company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.\n\nCollegium focuses on responsible pain management medications and neuropsychiatry, with JORNAY PM as its lead growth driver.","key_figures":{},"named_entities":{"people":[{"name":"Ian Karp","role":"Head of Investor Relations"},{"name":"Danielle Jesse","role":"Director, Investor Relations"},{"name":"Jessica Cotrone","role":"Senior Vice President, Communications & Corporate Affairs"}],"products":["JORNAY PM"],"companies":[{"name":"Collegium Pharmaceutical, Inc.","ticker":"COLL"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-23T15:16:05.460Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.730Z"}},"durationMs":16834,"modelName":"glm-4.7"}}